Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.50 |
| ▸ | PTGIR | P43119 | 6/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13802411 | 0.95 | ABCB1 (0.56) | ABCB1PTGS1PTGS2PTGDR2PTGIR | |
| SCHEMBL13802437 | 0.95 | ABCB1 (0.56) | ABCB1PTGS1PTGS2PTGDR2PTGIR | |
| SCHEMBL13802385 | 0.94 | ABCB1 (0.55) | ABCB1PTGS1PTGS2PTGDR2PTGIR | |
| SCHEMBL12480026 | 0.80 | ABCB1 (0.64) | ABCB1PTGS1PTGS2PTGDR2PTGIR | |
| SCHEMBL2004428 | 0.79 | PTGS1 (0.56) | ABCB1PTGS1PTGS2PTGDR2LMNA | |
| Delmetacin SCHEMBL286727 | 0.79 | ABCB1 (0.82) | ABCB1PTGS1PTGS2PTGDR2PTGIR | |
| SCHEMBL13802417 | 0.79 | ABCB1 (0.62) | ABCB1PTGS1PTGS2PTGDR2PTGIR | |
| SCHEMBL2004074 | 0.79 | PTGS1 (0.58) | ABCB1PTGS1PTGS2PTGDR2LMNA | |
| SCHEMBL17102845 | 0.78 | ABCB1 (0.61) | ABCB1PTGS1PTGS2PTGDR2PTGIR | |
| SCHEMBL13802433 | 0.78 | ABCB1 (0.61) | ABCB1PTGS1PTGS2PTGDR2PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | ABCB1 139/4885PTGS1 2198/4885PTGS2 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.